Tasigna 150mg (Nilotinib)

Contact us for more information
Wishlist Compare
Brand nameTasignaInternational trade nameTasignaActive substanceNilotinibStrength150mgCategoryAnti Cancer

Description  of  Tasigna 150mg (Nilotinib 150mg)

Tasigna 150mg (Nilotinib 150mg) is cancer drugs, the main ingredient which is used as Lapatinib, which prohibits growth of the tumor cells. Nilotinib is sold under the brand name Tasigna 150mg (Nilotinib 150mg) which is a targeted cancer medication Tasigna 150mg (Nilotinib 150mg) Capsule belongs to the class of kinase inhibitors. The medicine Tasigna 150mg (Nilotinib 150mg) in children younger than 1 year has no safety and efficacy not been established The drug Tasigna 150mg (Nilotinib 150mg) is a prescription drugs, which is used under the knowledge of medical oncologist.

INDICATIONS of  Tasigna 150mg (Nilotinib 150mg)

Tasigna 150mg (Nilotinib 150mg) Capsules are primarily indicated for the treatment in adults patients with chronic and accelerated phase philadelphia chromosome positive chronic myelogenous leukemia (ph+ cml) resistant or intolerant to prior therapy which involves imatinib

MECHANISM OF ACTION  of  Tasigna 150mg (Nilotinib 150mg)

CML: chronic myelogenous leukemia is caused by BCR-ABL oncogene.Tasigna 150mg (Nilotinib 150mg) (Nilotinib mechanism of action ) is a kinase inhibitor, which prohibits BCR-ABL kinase activity. Binding of Tasigna 150mg (Nilotinib 150mg) to the ATP-binding site of BCR-ABL protein. The drug Tasigna 150mg (Nilotinib 150mg) prevents the proliferation of murine leukemic cell lines and human cell lines derived from patients with Philadelphia positive CML

Absorption of  Tasigna 150mg (Nilotinib 150mg)

The Tasigna 150mg (Nilotinib 150mg) has bioavailability about 50% The time of peak plasma concentration is occurred within 3 hours after administration.

Distribution of  Tasigna 150mg (Nilotinib 150mg)

The Tasigna 150mg (Nilotinib 150mg) has serum protein binding is approximately 98% The Nilotinib blood to serum ratio is 0.68

Metabolism of  Tasigna 150mg (Nilotinib 150mg)

Tasigna 150mg (Nilotinib 150mg) is metabolized via CYP3A4 mediated oxidation. The prime flowing component in the blood stream is Nilotinib.

Excretion of  Tasigna 150mg (Nilotinib 150mg)

The half life period of Tasigna 150mg (Nilotinib 150mg) Capsule is approximately 17 hours. The mean apparent clearance value is 29L/hr.
Effect of food:
The effect of drug is increased to 82% when the dose was given 30 minutes after a high fat meal when compared to fasted patient.

 SIDE EFFECTS  of  Tasigna 150mg (Nilotinib 150mg)

General: Fatigue, pyrexia, asthenia, peripheral edema, face edema
Pulmonary: Dyspnae , Cough, oropharyngeal pain,
Skin: Rash, Pruritus, alopecia, dry skin
GIT: Nausea, constipation, diarrhea, vomiting, upper abdominal pain, dyspepsia
Nerve system: Dizziness , Headache,
Vascular: Hypertension
Muscle: Myalgia, arthralgia, muscle spasm, pain in extremity, back pain
Infections & infestations: Nasopharyngitis, upper respiratory tract infection, influenza, gastroenteritis
Eye: Eyelid edema, periorbital edema
Psychiatric: Insomnia , this are the Tasigna 150mg (Nilotinib 150mg) side effects.

PRECAUTIONS  of  Tasigna 150mg (Nilotinib 150mg)

Tasigna 150mg (Nilotinib 150mg) may cause thrombocytopenia, neutropenia and anemia, so check blood counts periodically to reduce these complications
Embryo fetal damage:
While using this in pregnancy then the drug Tasigna 150mg (Nilotinib 150mg) causes fetal damage Examine the patients properly who are stop the Tasigna 150mg (Nilotinib 150mg) therapy, the range of Bcr-Abl transcripts level. Use the drug with caution while using Tasigna 150mg (Nilotinib 150mg) in patient who are suffered with Hypokalemia Hypomagnesemia Hepatotoxicity Electrolyte abnormalities
Long QT syndrome :
Monitor ECG frequently Avoid concomitant use of Tasigna 150mg (Nilotinib 150mg) with anti-arrhythmia agents Provide supportive measures
Pancreatitis and elevated lipase :
Patient suffering with pancreatitis may have serum lipase levels increase, this may results in abdominal symptoms and to decrease the problems, treatment should be postponed & undergone with appropriate diagnostics. Test serum lipase value periodically.
Tumor lysis syndrome:
Maintain with sufficient hydration Balance the level of uric acid before starting the treatment.

DRUG INTERACTION  of  Tasigna 150mg (Nilotinib 150mg)

While interaction of strong CYP3A inhibitors with  Tasigna 150mg (Nilotinib 150mg)  leads to increase nilotinib concentrations compared to while using Tasigna 150mg (Nilotinib 150mg) alone Concomitant use with strong CYP3A inducer leads to reduce nilotinib concentration Tasigna 150mg (Nilotinib 150mg) interaction With proton pump inhibitors: decrease the Tasigna 150mg (Nilotinib 150mg) efficacy Avoid combination of Tasigna 150mg (Nilotinib 150mg) with drugs that may prolong the QT interval like anti-arrhythmic drugs.

CONTRAINDICATION of  Tasigna 150mg (Nilotinib 150mg)

Tasigna 150mg (Nilotinib 150mg) Capsule is contraindicated in the patients who are having; Hypokalemia Hypomagnesemia Long QT syndrome

PREGNANCY  of Tasigna 150mg (Nilotinib 150mg)

Pregnancy category: D While pregnancy condition and women who become pregnant , avoid using of Tasigna 150mg (Nilotinib 150mg) Capsule because it will cause fetal damage.

LACTATION  of Tasigna 150mg (Nilotinib 150mg)

Tasigna 150mg (Nilotinib 150mg) not recommended in breastfeeding mothers

DOSAGE of  Tasigna 150mg (Nilotinib 150mg)

The usual dose of Tasigna 150mg (Nilotinib 150mg) Capsule should be given as twice daily at 12 hours time intervals Tasigna 150mg (Nilotinib 150mg) must be administer on an empty stomach Taking of food should not be at least 1 hour after the dose is taken or 2 hours before the dose is taken Who are unable to taken the Tasigna 150mg (Nilotinib 150mg) capsules, the patients can be dispersed the Capsule in one teaspoon of applesauce. This Capsule should be administer immediately within 15 minutes Tasigna 150mg (Nilotinib 150mg) should be combination with hematopoietic growth factors such as erythropoietin or G-CSF Also concomitant use with hydroxyurea or anagrelide

Dosage in adult patients with Philadelphia positive CML-CP :

The regular dose of the Tasigna 150mg (Nilotinib 150mg) Capsule in this condition given is 300mg should be given orally as twice daily.

With resistant or intolerant Philadelphia positive CML-CP and CML-AP:

The normal dose is 400mg should be administered as orally twice in a day.

In pediatrics:

The normal dose 230mg/m2 should be administer orally twice daily The maximum dose of Capsule Tasigna 150mg (Nilotinib 150mg) is 400mg.



STORAGE  of  Tasigna 150mg (Nilotinib 150mg)

Stored at between 68℉ to 77℉ (20℃ to 25℃) room temperature keep away from heat, moisture and light.

MISSED DOSE of  Tasigna 150mg (Nilotinib 150mg)

If patients missed to have the dose , then administer the dose of Tasigna 150mg (Nilotinib 150mg) should be take within the time, or the missed dose should be swapped and continue the next dosing schedule. Consult with your doctor for more clarification

Brand name:
International trade name:
Active substance:
Anti Cancer
28 capsules
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India